4.7 Review

Right Heart Adaptation to Pulmonary Arterial Hypertension Physiology and Pathobiology

期刊

出版社

ELSEVIER SCIENCE INC
DOI: 10.1016/j.jacc.2013.10.027

关键词

echocardiography; heart failure; MRI; myocardium; pulmonary artery hypertension; right ventricle

资金

  1. Actelion
  2. Bayer
  3. GlaxoSmithKline
  4. United Therapeutics
  5. Lilly
  6. Pfizer
  7. Novartis
  8. Gilead
  9. GeNO
  10. National Institutes of Health
  11. Dutch Heart Foundation [NHS-2012T010]
  12. AIRES
  13. Ikaria
  14. Lung LLC
  15. Unither Biotech
  16. AOP
  17. National Heart, Lung, and Blood Institute [P50 HL084946, R01 HL114910]

向作者/读者索取更多资源

Survival in patients with pulmonary arterial hypertension (PAH) is closely related to right ventricular (RV) function. Although pulmonary load is an important determinant of RV systolic function in PAH, there remains a significant variability in RV adaptation to pulmonary hypertension. In this report, the authors discuss the emerging concepts of right heart pathobiology in PAH. More specifically, the discussion focuses on the following questions. 1) How is right heart failure syndrome best defined? 2) What are the underlying molecular mechanisms of the failing right ventricle in PAH? 3) How are RV contractility and function and their prognostic implications best assessed? 4) What is the role of targeted RV therapy? Throughout the report, the authors highlight differences between right and left heart failure and outline key areas of future investigation. (C) 2013 by the American College of Cardiology Foundation

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据